NIOX Group Plc (CSSPF) Stock
Niox Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis and management of asthma. It offers NIOX VERO, a non-invasive point-of-care system that provides fractional exhaled nitric oxide (FeNO) measurements.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About NIOX Group Plc
Niox Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis and management of asthma. It offers NIOX VERO, a non-invasive point-of-care system that provides fractional exhaled nitric oxide (FeNO) measurements. The company was founded by Steven Harris and Charles Stuart Webb Swingland on May 19, 2006 and is headquartered in Oxford, the United Kingdom.
NIOX Group Plc is headquartered in GB.
NIOX Group Plc (CSSPF) stock trades at $0.75 with a market capitalization of $315.65M. The stock is valued at a price-to-earnings (P/E) ratio of 36.57, price-to-book of 3.55, price-to-sales of 5.34. Over the past 52 weeks the stock has ranged between $0.75 and $0.92, and currently trades 18.5% below its 52-week high. It pays a dividend yielding 2.67%.
On profitability, NIOX Group Plc generates a return on equity (ROE) of 10.14%, return on capital employed of 15.71%, an operating margin of 21.97%, a net profit margin of 14.37%.
Official website: www.niox.com